 Home > Medical News > Medical Research Articles > AffaMed Therapeutics announces that AM006 for the treatment of Parkinson's disease has been approved for IIb clinical research in China

AffaMed Therapeutics announces that AM006 for the treatment of Parkinson's disease has been approved for IIb clinical research in China

 Last Update: 2021-06-30
 Source: Internet
 Author: User

Tags

united states corporation

nonlinear control system

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

AffaMed Therapeutics, a clinical-stage innovative biomedical company dedicated to meeting the global needs for the treatment of ophthalmology, neurological and psychiatric diseases, today announced that the National Medical Products Administration (NMPA) has approved the global IIb clinical trial application (CTA) led by it.
To evaluate the safety and effectiveness of AM006 for the treatment of patients with early Parkinson's disease (PD)
.

AM006 is a new type of non-ergot dopamine receptor agonist (DA), which can be clinically developed to improve PD symptoms by stimulating striatal dopamine receptors

PD is a common clinical degenerative disease of the nervous system, which mainly manifests as motor symptoms such as resting tremor, bradykinesia, muscle rigidity and postural balance disorders, as well as non-motor symptoms such as emotional and cognitive dysfunction
.

The exact cause of PD is currently unknown.

Dr.
Dayao Zhao, CEO of AffaMed, said: “In China and around the world, patients with Parkinson’s disease have a huge demand for treatment
.

We are very pleased to advance AM006’s NMPA clinical trial within 7 months after signing the product license agreement.

AM006 is an innovative drug with great potential to treat PD
.

The results of previous studies suggest that the drug may reduce the risk of certain adverse reactions (such as valvular heart disease, drowsiness, sudden sleep and impulse control disorders) that have been reported by existing DA

Globally, AM006 is in the IIb clinical trial phase, and the clinical application for this project has been approved in Singapore and China in April and May 2021, respectively

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Semiglutide 99% Hot Sale Pharmaceutical Best Service Pharmaceutical Producer

CAS No.:

pharm grade

$140.00/G FOB

Carboxylated Styrene-Butadiene latex (XSBR)

CAS No.: 25085-39-6

Different Grade

$0.1/KG EXW

High quality Pure 99% 4,16-Androstadien-3-one Androstadienone raw powder cas 4075-07-4

CAS No.: 4075-07-4

Pharmacy Grade

$14-16/G FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.